
    
      The purpose of this study is:

        -  to compare the progression free survival (PFS) of AIs/everolimus to AIs administered as
           maintenance therapy in HR+ advanced breast cancer patients with disease control
           (Complete Response (CR), Partial Response (PR) or Stable Disease (SD))after 1st line
           chemotherapy.

        -  To evaluate the overall survival

        -  To assess the safety profile

        -  To evaluate the response rate
    
  